Cystic Fibrosis Foundation
61
15M
44
0.88
16
0.28
14
- Areas of investment
Summary
Cystic Fibrosis Foundation appeared to be the Corporate Investor, which was created in 1955. The main department of described Corporate Investor is located in the Bethesda. The company was established in North America in United States.
Considering the real fund results, this Corporate Investor is 26 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 deals per year. The higher amount of exits for fund were in 2006. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Cystic Fibrosis Foundation works on 2 percentage points more the average amount of lead investments.
The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Cystic Fibrosis Foundation, startups are often financed by Epidarex Capital, Imperial Innovations, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Aligo Innovation, Shionogi, RSJ Investments SICAV a.s.. In the next rounds fund is usually obtained by U.S. Venture Partners (USVP), RBC Capital Markets, Novo Holdings.
The fund has exact preference in some founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biopharma. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline 4D Molecular Therapeutics, Laurent Pharmaceuticals, Parion Sciences
Investments analytics
Analytics
- Total investments
- 61
- Lead investments
- 16
- Exits
- 14
- Rounds per year
- 0.88
- Follow on index
- 0.28
- Investments by industry
- Biotechnology (51)
- Health Care (30)
- Pharmaceutical (29)
- Therapeutics (19)
- Medical (11) Show 18 more
- Investments by region
-
- United States (43)
- United Kingdom (5)
- Israel (4)
- Canada (8)
- Switzerland (1)
- Peak activity year
- 2022
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 42M
- Group Appearance index
- 0.31
- Avg. company exit year
- 10
- Avg. multiplicator
- 0.60
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics | 16 Jun 2020 | Biotechnology, Drug Discovery, Genetics | Late Stage Venture | 75M | United States, California |
| Sionna Therapeutics | 06 Mar 2024 | Health Care, Genetics, Medical, Pharmaceutical, Therapeutics | Late Stage Venture | 182M | United States, Massachusetts, Natick |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.